Oxytocin's Effect on Attention Training

October 26, 2018 updated by: Benjamin Becker, University of Electronic Science and Technology of China

An Eye-tracking Study to Investigate Oxytocin's Effect on Attentional Bias Training

This study aims to investigate oxytocin's effect on attentional bias training. Healthy participants will undergo a dot-probe task-based training to direct their attention away from negative stimuli (as compared to neutral). Effects of the training will be assessed using an eye-tracking anti-saccade task.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

In this study, a dot-probe task will be used to examine if subjects show an attentional bias towards negative stimuli and whether the bias can be modified using a subsequent attentional bias training. During this training participants learn to direct their attention away from threatening stimuli. In a between-subject placebo controlled design participants will receive either intranasal oxytocin or placebo before the training to examine whether oxytocin could facilitate the effects of the attention training. Effects of the training and of oxytocin on the training will be assessed by means of an eye-tracking anti-saccade task. Based on previous studies showing the strongest effects of threat-attentional bias training in high anxious subjects, the study will recruit participants with an elevated trait anxiety.

Study Type

Interventional

Enrollment (Anticipated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Sichuan
      • Chendu, Sichuan, China, 611731
        • Recruiting
        • School of Life Science and Technology, University of Electronic Science and Technology of China
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 30 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • male participants with elevated trait anxiety (> 45 scores as assessed with the State and Trait Anxiety Inventory, Spielberger, 1983)
  • without past or current psychiatric or neurological disorders

Exclusion Criteria:

  • history of head injury
  • medical or psychiatric illness
  • smoking or drinking 24 hours before the experiment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: oxytocin group
oxytocin treatment
intranasal administration of oxytocin (24IU)
Placebo Comparator: placebo group
placebo treatment
intranasal administration of placebo (24IU)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Reaction time (RT) difference - oxytocin effects
Time Frame: Before drug administration (pre-treatment baseline) and 55 minutes after drug administration
Difference before and after oxytocin administration: reaction time to negative and neutral stimuli in the dot-probe task
Before drug administration (pre-treatment baseline) and 55 minutes after drug administration
Reaction time (RT) difference - training effects
Time Frame: Before drug administration - 55-90 minutes after drug administration
Difference before and after training: reaction time to negative and neutral stimuli in the dot-probe task
Before drug administration - 55-90 minutes after drug administration
Saccade latency difference - training effects
Time Frame: Before drug administration - 55-90 minutes after drug administration
Difference before and after training in saccade latency in the anti-saccade task
Before drug administration - 55-90 minutes after drug administration

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 25, 2016

Primary Completion (Anticipated)

December 30, 2018

Study Completion (Anticipated)

December 30, 2018

Study Registration Dates

First Submitted

April 17, 2017

First Submitted That Met QC Criteria

April 20, 2017

First Posted (Actual)

April 25, 2017

Study Record Updates

Last Update Posted (Actual)

October 29, 2018

Last Update Submitted That Met QC Criteria

October 26, 2018

Last Verified

October 1, 2018

More Information

Terms related to this study

Other Study ID Numbers

  • UESTC-neuSCAN-32

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on Oxytocin

3
Subscribe